Datapharm Australia Pty Signs Clinical Trial Services Agreement with Phoenix Eagle Company Pty Ltd
At the BIO meeting in Atlanta (May 18-21), the Chairman of Datapharm Australia Pty Ltd, Dr Helen Allars, signed an agreement with Mark Richardson, Managing Director of Phoenix Eagle Company Pty Ltd, based in Western Australia, to conduct the first randomized clinical trial of its OPAL A papaya product in healing venous and pressure ulcers. The randomized study will be conducted in Melbourne with a key opinion leader in the field of wound healing, Associate Professor Michael Woodward, as Principal Investigator. Datapharm’s medical director, Dr Lynette Tozer, has recently commenced writing up the case histories of the use of the papaya product in the treatment of chronic pressure ulcers in quadriplegic patients at an Australian hospital. Her initial observations indicate that this natural product has the potential to become a significant wound healing medicine.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
